
    
      It is an open, single-arm, multi-center clinical trial conducted in China, and plan to
      Recruiting 72 patients in the elderly without systemic chemotherapy. Patents receive 12mg
      anlotinib orally daily on day 1to 14 of a 21-day cycle until progression of disease, assess
      safety and efficacy of the drug.
    
  